Endocrine System Diseases clinical trials

The registry lists 322 studies for Endocrine System Diseases across more than 10 countries. 51 are recruiting or about to start. 47 of them are mainly about Endocrine System Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 111 narrower conditions too, such as Diabetes Mellitus, Type 2: 37,015 studies, 6,733 open.

Get an email when these change. Save the Endocrine System Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 183
Recruiting: 42
Status unknown: 41
Terminated: 20
Active, not recruiting: 18
Not yet recruiting: 8

Phase

Phase 2: 60
Phase 3: 48
Phase 1: 37
Phase 4: 9
Early Phase 1: 2

Where

United States: 144
Canada: 33
United Kingdom: 28
China: 28
France: 26
Germany: 25

Who runs them

National Center for Research Resources (NCRR) (26) · Eli Lilly and Company (13) · University of Pittsburgh (8) · AstraZeneca (7) · Pfizer (6) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (6) · University Hospital, Basel, Switzerland (5) · Merck Sharp & Dohme LLC (5)

What is being tested here

Drugs under test in Endocrine System Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Testosterone	2	1	5
Tirzepatide	1	4	6
Lonapegsomatropin	1	4	4
Palopegteriparatide	1	3	4
Berobenatide	1	2	2
Linsitinib	1	2	2
Dehydroepiandrosterone	1	1	2
Finasteride	1	1	2
Testosterone 17 beta-cypionate	1	1	1
Orforglipron	1	1	1

Drug classes tested here GLP-1 receptor agonists 2 open · Tyrosine kinase inhibitors (TKIs) 2 open · Androgens 2 open · SGLT2 inhibitors 7 · DPP-4 inhibitors 7

Coming up

11phase 3 studies under way

19studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

May 2027A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting · Phase 3 · Eli Lilly and Company
Jun 2027A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism · Phase 3 · Ascendis Pharma Bone Diseases A/S
Oct 2027A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · Pfizer
Nov 2026Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders · IRCCS San Raffaele
Nov 2026Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions · Sarah Schlegel
Nov 2026Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers · Tides Medical
Nov 2026Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs · C5 Biomedical
Dec 2026Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM · Gaia AG
Dec 2026Telehealth Music Therapy for Adults With Endocrine Disorder and Depression · Appalachian State University
Dec 2026Environment, Inflammation and Metabolic Diseases Study · Qifu Li

Who these studies take

Of the 42 Endocrine System Diseases studies recruiting now, 20 (48%) set no upper age limit and 15 (36%) stop at 75 or younger. 10 (24%) take children under 18. 4 (10%) are for women only and 2 (5%) for men only; 10 (24%) take healthy volunteers.

Recruiting studies that take each age, of 42
Age	Women	Men
10	7 (17%)	7 (17%)
18	37 (88%)	36 (86%)
30	37 (88%)	36 (86%)
40	37 (88%)	36 (86%)
50	33 (79%)	35 (83%)
65	33 (79%)	35 (83%)
75	27 (64%)	29 (69%)
85	25 (60%)	27 (64%)

Across all 322 studies, recruiting or not: 52% stop at 75 or younger and 37% at 65; 24% take children; 12% are for women only and 6% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Endocrine System Diseases studies take

Of 29 phase 3 interventional studies under Endocrine System Diseases, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	39 mo23–49 · 19 studies	—	—
Phase 3	26 mo17–36 · 29 studies	25 mo17–34 · 27 studies	—
Interventional, no phase	23 mo11–35 · 52 studies	—	23 mo11–39 · 45 studies
Observational	43 mo13–339 · 32 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 322. Browse all 322 → or search them.